146 related articles for article (PubMed ID: 29984015)
1. Bradycardia during Induction Therapy with All-
Chen PZ; Wu YJ; Wu CC; Wang YW
Case Rep Hematol; 2018; 2018():4938797. PubMed ID: 29984015
[TBL] [Abstract][Full Text] [Related]
2. [Adams-Stokes attack due to complete atrioventricular block in a patient with acute promyelocytic leukemia during remission induction therapy using all-trans retinoic acid].
Yamauchi T; Arai H; Taga M; Amaya N; Lee JD; Ueda T
Rinsho Ketsueki; 2005 Mar; 46(3):206-10. PubMed ID: 16447716
[TBL] [Abstract][Full Text] [Related]
3. All-trans retinoic acid-induced, life-threatening complete atrioventricular block.
Shih CH; Wu HB
J Chin Med Assoc; 2015 May; 78(5):316-9. PubMed ID: 25726499
[TBL] [Abstract][Full Text] [Related]
4. [Effect of all-trans retinoic acid on the newly diagnosed acute promyelocytic leukaemia: our experience].
Rolovitsh Z; Cholovitsh M; Elezovitsh I; Vidovitsh A; Radoshevitsh-Radojkovitsh N; Boshkovitsh D; Novak A; Basara N
Srp Arh Celok Lek; 1995; 123(11-12):279-85. PubMed ID: 16296239
[TBL] [Abstract][Full Text] [Related]
5. Distinct Characteristics of Sweet's Syndrome of the Scrotum Caused by All-
Imataki O; Yoshida S; Kaji T; Kida JI; Kubo H; Uemura M; Fujita H; Kadowaki N
Case Rep Oncol; 2021; 14(3):1466-1474. PubMed ID: 34899238
[TBL] [Abstract][Full Text] [Related]
6. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.
Burnett AK; Russell NH; Hills RK; Bowen D; Kell J; Knapper S; Morgan YG; Lok J; Grech A; Jones G; Khwaja A; Friis L; McMullin MF; Hunter A; Clark RE; Grimwade D;
Lancet Oncol; 2015 Oct; 16(13):1295-305. PubMed ID: 26384238
[TBL] [Abstract][Full Text] [Related]
7. Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial.
Zhu HH; Wu DP; Du X; Zhang X; Liu L; Ma J; Shao ZH; Ren HY; Hu JD; Xu KL; Wang JW; Song YP; Fang MY; Li J; Yan XY; Huang XJ
Lancet Oncol; 2018 Jul; 19(7):871-879. PubMed ID: 29884593
[TBL] [Abstract][Full Text] [Related]
8. Comparison of induction therapy in non-high risk acute promyelocytic leukemia with arsenic trioxide or in combination with ATRA.
Ghavamzadeh A; Jalili M; Rostami S; Yaghmaie M; Aliabadi LS; Mousavi SA; Vaezi M; Fumani HK; Jahani M; Alimoghaddam K
Leuk Res; 2018 Mar; 66():85-88. PubMed ID: 29407588
[TBL] [Abstract][Full Text] [Related]
9. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia.
Lo-Coco F; Avvisati G; Vignetti M; Thiede C; Orlando SM; Iacobelli S; Ferrara F; Fazi P; Cicconi L; Di Bona E; Specchia G; Sica S; Divona M; Levis A; Fiedler W; Cerqui E; Breccia M; Fioritoni G; Salih HR; Cazzola M; Melillo L; Carella AM; Brandts CH; Morra E; von Lilienfeld-Toal M; Hertenstein B; Wattad M; Lübbert M; Hänel M; Schmitz N; Link H; Kropp MG; Rambaldi A; La Nasa G; Luppi M; Ciceri F; Finizio O; Venditti A; Fabbiano F; Döhner K; Sauer M; Ganser A; Amadori S; Mandelli F; Döhner H; Ehninger G; Schlenk RF; Platzbecker U; ; ;
N Engl J Med; 2013 Jul; 369(2):111-21. PubMed ID: 23841729
[TBL] [Abstract][Full Text] [Related]
10. Role of cytarabine in paediatric acute promyelocytic leukemia treated with the combination of all-trans retinoic acid and arsenic trioxide: a randomized controlled trial.
Zhang L; Zou Y; Chen Y; Guo Y; Yang W; Chen X; Wang S; Liu X; Ruan M; Zhang J; Liu T; Liu F; Qi B; An W; Ren Y; Chang L; Zhu X
BMC Cancer; 2018 Apr; 18(1):374. PubMed ID: 29615003
[TBL] [Abstract][Full Text] [Related]
11. Cost-Effectiveness Analysis of Treating Acute Promyelocytic Leukemia Patients With Arsenic Trioxide and Retinoic Acid in the United States.
Tallman M; Lo-Coco F; Barnes G; Kruse M; Wildner R; Martin M; Mueller U; Tang B
Clin Lymphoma Myeloma Leuk; 2015 Dec; 15(12):771-7. PubMed ID: 26361645
[TBL] [Abstract][Full Text] [Related]
12. [Arsenic trioxide in combination with all-trans retinoic acid for acute promyelocytic leukemia: a systematic review and meta-analysis].
Xu SN; Chen JP; Liu JP; Xia Y
Zhong Xi Yi Jie He Xue Bao; 2009 Nov; 7(11):1024-34. PubMed ID: 19912733
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of early switching to an outpatient therapy model using oral arsenic plus retinoic acid based-regimen in newly diagnosed acute promyelocytic leukemia.
Lou Y; Tong H; Yu W; Wei J; Xu W; Mao L; Jin J
Leuk Res; 2019 Aug; 83():106168. PubMed ID: 31202077
[TBL] [Abstract][Full Text] [Related]
14. Arsenic trioxide and all-trans retinoic acid (ATRA) treatment for acute promyelocytic leukemia in all risk groups: study protocol for a randomized controlled trial.
Zhang X; Zhang H; Chen L; Wang M; Xi J; Liu X; Xie M; Li D; Gulati ES; Gong S; Wang H
Trials; 2018 Sep; 19(1):476. PubMed ID: 30185214
[TBL] [Abstract][Full Text] [Related]
15. [All-trans retinoic acid/arsenic trioxide combination therapy for a patient with acute promyelocytic leukemia on dialysis].
Nagao R; Hosoba R; Yahagi Y; Gunji T; Uryu H; Hattori D; Momoki M; Yamazaki H
Rinsho Ketsueki; 2019; 60(10):1431-1435. PubMed ID: 31695003
[TBL] [Abstract][Full Text] [Related]
16. CNS relapses of acute promyelocytic leukemia after all-trans retinoic acid.
Burry LD; Seki JT
Ann Pharmacother; 2002 Dec; 36(12):1900-6. PubMed ID: 12452754
[TBL] [Abstract][Full Text] [Related]
17. Maintenance therapy with all-trans retinoic acid and arsenic trioxide improves relapse-free survival in adults with low- to intermediate-risk acute promyelocytic leukemia who have achieved complete remission after consolidation therapy.
Liang B; Zheng Z; Shi Y; Chen J; Hu X; Qian H; Shen Z; Jiang S; Yu K; Feng J
Onco Targets Ther; 2017; 10():2305-2313. PubMed ID: 28490888
[TBL] [Abstract][Full Text] [Related]
18. [Sinus bradyarrhythmia during administration of all-trans retinoic acid in a patient with acute promyelocytic leukemia].
Maruhashi K; Wada H; Taniguchi M; Koizumi S
Rinsho Ketsueki; 1996 May; 37(5):443-7. PubMed ID: 8691592
[TBL] [Abstract][Full Text] [Related]
19. New retinoids and arsenic compounds for the treatment of refractory acute promyelocytic leukemia: clinical and basic studies for the next generation.
Kitamura K; Kiyoi H; Yoshida H; Tobita T; Takeshita A; Ohno R; Naoe T
Cancer Chemother Pharmacol; 1997; 40 Suppl():S36-41. PubMed ID: 9272132
[TBL] [Abstract][Full Text] [Related]
20. [Comparison of efficacy and adverse effects between arsenic trioxide and all-trans retinoic acid in patients with acute promyelocytic leukemia].
Jiao L; Wang SJ; Zhuang JL; Zhao YQ; Zhou DB; Xu Y; Han B; Zhang W; Duan MH; Zou N; Zhu TN; Shen T
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2009 Oct; 31(5):555-8. PubMed ID: 19968069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
